174 results on '"Bossé, Dominick"'
Search Results
2. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study
3. Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, Canada.
4. Potential insights from population kinetic assessment of progression-free survival curves
5. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
6. A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model
7. Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence
8. Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer
9. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
10. What Attributes Matter Most in Physicians? Exploratory Findings from a Single-Centre Survey of Stakeholder Priorities in Cancer Care at a Canadian Academic Cancer Centre
11. Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System
12. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
13. Radiogenomics in renal cell carcinoma
14. Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis
15. Immunotherapy in the Elderly
16. Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence
17. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
18. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma
19. Data from The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
20. Data from Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
21. Supplementary Data from The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
22. Supplementary Tables 1 through 4 from Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
23. Supplementary Table, Supplementary Figure Legends from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
24. Figure S2 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
25. Evolution in upfront treatment strategies for metastatic RCC
26. Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis
27. CANCER: Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
28. A survey of physician perception and practices regarding pharmacological thromboprophylaxis during chemotherapy for bladder cancer
29. Attitudes towards open‐label versus placebo‐control designs in oncology randomized trials: A survey of medical oncologists
30. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019
31. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021
32. Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts
33. Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic
34. Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial
35. Response of Primary Renal Cell Carcinoma to Systemic Therapy
36. Metabolomic adaptations and correlates of survival to immune checkpoint blockade
37. Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.
38. Population kinetics of progression free survival (PFS).
39. Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
40. Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).
41. The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity
42. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma
43. Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
44. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
45. Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.
46. Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
47. Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS).
48. Radiogenomics in renal cell carcinoma
49. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
50. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.